Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iLeadBMS CXCR7 agonist (neurodegenerative)
- Development stage
- Preclinical
- Lead developer
- iLeadBMS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
iLeadBMS is developing an unnamed, first-in-class, orally available small molecule CXCR7 agonist specifically for the treatment of neurodegenerative diseases, including multiple sclerosis (MS). This compound is designed with blood-brain barrier (BBB) penetration potential to target the central nervous system. By activating the C-X-C chemokine receptor type 7 (CXCR7), also known as atypical chemokine receptor 3 (ACKR3), the drug aims to upregulate the receptor's neuroprotective functions and maintain CNS homeostasis. This program is distinct from iLeadBMS's other CXCR7 agonist, IL2112, which targets fibrotic and autoimmune conditions.
- Other names
- CXCR7 agonist (neurodegenerative diseases)ACKR3 agonistACKR-3 agonistACKR 3 agonist
02
Targets
CXCR7 (CXC chemokine receptor 7)
Beyond the preview
Go deeper on iLeadBMS CXCR7 agonist (neurodegenerative).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iLeadBMS CXCR7 agonist (neurodegenerative).